Which topical cream should be prescribed for eczema?

Topical Corticosteroids Are the Mainstay Treatment for Eczema

For adults with eczema, prescribe topical corticosteroids as first-line anti-inflammatory therapy, combined with liberal emollient use. The specific potency should be matched to disease severity and body site, with mild-to-moderate potency steroids for facial/flexural areas and potent steroids for body/limb involvement 1, 2.

Treatment Algorithm

First-Line Approach

Emollients (foundational therapy):

• Prescribe 200-400g per week for adults 3
• Apply liberally and frequently (at least twice daily, ideally after bathing) 1
• Use as soap substitutes to avoid stripping natural skin lipids 1
• Choose cream-based for weeping lesions, ointment-based for dry skin 3

Topical Corticosteroids (TCS) - Primary anti-inflammatory:

• Mild potency (hydrocortisone 1-2.5%): Face, neck, flexures, genitalia 3, 2
• Moderate potency (clobetasone butyrate 0.05%): Mild-to-moderate disease on trunk/limbs 3
• Potent (betamethasone valerate 0.1%, mometasone 0.1%): Moderate-to-severe disease on body 3, 2
• Very potent (clobetasol propionate 0.05%): Severe flares, lichenified areas, short-term use only 3

Apply once or twice daily maximum—more frequent application provides no additional benefit 1

Evidence Supporting TCS Superiority

The 2024 Cochrane network meta-analysis of 291 studies (45,846 participants) demonstrated that potent TCS ranked among the most effective treatments across all efficacy outcomes 4. Specifically:

• Potent TCS showed OR 5.99 (95% CI 2.83-12.69) for symptom improvement 4
• Very potent TCS ranked highest for clinician-assessed signs (OR 8.34,95% CI 4.73-14.67) 4
• TCS were least likely to cause application-site reactions compared to other anti-inflammatory agents 4

Maintenance Therapy

After achieving control, transition to proactive maintenance:

• Apply medium-potency TCS twice weekly to previously affected areas 2
• This reduces flares and disease relapse with strong evidence support 2
• Continue daily emollient use throughout 1, 2

Alternative Anti-Inflammatory Options

When to Consider Alternatives

Switch from TCS if:

• Facial/eyelid involvement requiring prolonged treatment (steroid atrophy risk)
• Patient/parent steroid phobia despite education
• Inadequate response after 2-3 weeks of appropriate TCS use

Second-Line Topical Agents

Topical Calcineurin Inhibitors (TCI):

• Tacrolimus 0.1% ointment: Moderate-to-severe disease, particularly effective (ranked similarly to potent TCS in efficacy) 2, 4
• Pimecrolimus 1% cream: Mild-to-moderate disease 2
• Advantage: No skin atrophy risk, safe for facial/flexural use long-term 1, 2
• Disadvantage: Application-site burning/stinging in 30-40% initially (usually resolves within 1 week) 4

Newer Topical Agents (FDA-approved):

• Ruxolitinib 1.5% cream (JAK inhibitor): Ranked among most effective (OR 9.34 for IGA improvement), moderate-to-severe disease 5, 4
• Crisaborole 2% ointment (PDE-4 inhibitor): Mild-to-moderate disease, but ranked among least effective in network meta-analysis 2, 4
• Tapinarof 1% cream (AhR agonist): Mild-to-moderate disease 5
• Roflumilast 0.15% cream (PDE-4 inhibitor): Mild-to-moderate disease 5

The 2025 AAD guidelines provide strong recommendations for tapinarof and roflumilast with concomitant topical therapy 5, though the 2024 Cochrane analysis ranked PDE-4 inhibitors among the least effective options 4.

Critical Safety Considerations

TCS Safety Profile

Short-term use (median 3 weeks):

• No evidence of increased skin thinning with any potency 4
• Minimal risk of hypothalamic-pituitary-adrenal axis suppression with low-potency TCS 6
• Use potent/very potent preparations cautiously and for limited periods only 1

Long-term use (6-60 months):

• Increased skin thinning risk documented with mild-to-potent TCS versus TCI 4
• This supports twice-weekly maintenance dosing rather than continuous daily application

Application-Site Reactions

Network meta-analysis of 18,992 participants showed 4:

• Highest reaction rates: Tacrolimus 0.1% (OR 2.2), crisaborole 2% (OR 2.12)
• Lowest reaction rates: All TCS potencies (protective compared to vehicle)

Common Pitfalls to Avoid

1. Underprescribing emollients: Most children receive insufficient quantities (median 1500g/year when 200-400g/week needed) 7

2. Steroid phobia: Educate that appropriate TCS use is safe and more effective than alternatives for acute flares 1

3. Wrong potency for site: Never use potent/very potent TCS on face—use mild potency or TCI instead 3

4. Inadequate treatment duration: Apply until lesions clear (typically 1-2 weeks), not just until "better" 1

5. Stopping all treatment when clear: Transition to maintenance therapy rather than complete cessation 2

Adjunctive Considerations

Antihistamines: Only sedating types (hydroxyzine 10-25mg at bedtime) may help sleep during severe pruritus—non-sedating antihistamines have no value 1, 8

Antibiotics: Reserve for clinically evident secondary bacterial infection (honey-colored crusting, weeping, failure to respond to appropriate anti-inflammatory therapy)—flucloxacillin is first-line for S. aureus 1

Bleach baths: Weak evidence for benefit; may reduce severity in moderate-to-severe disease with secondary infection, but not more effective than water baths alone 8, 2